the Use of dexamethasone at a 30 percent reduced mortality among the most severe coronavirus infection patients who are on artificial ventilation of lungs, – said the head of the who Dr. Tedros Gareiss at a briefing in Geneva.
the Statement of the head of the who data is based on research about the effectiveness of dexamethasone in patients with coronavirus infection with moderate and severe course of the disease, published by the British medical. Tedros Gareiss call these results scientific breakthrough in the treatment COVID-19. “This is the first drug that showed a decrease in mortality among patients with COVID-19 who require mechanical ventilation and oxygen support,” said Gareiss.
When therapy with dexamethasone, as demonstrated by the study, mortality among patients on mechanical ventilation decreased by 30 percent, and among patients who are on oxygen support at 20 per cent.
“This is great news, I congratulate the government of Britain, Oxford University and many hospitals, and patients in the UK who have contributed to this life-saving scientific breakthrough,” – said the head of the who.
Dexamethasone is a synthetic glucocorticoid (GCS), which is used from 1960-ies to reduce inflammation in many diseases. “He was included in the model list of essential medicines of the who since 1977 in several. He is currently patented and available in most countries,” said who. The drug has anti-inflammatory, antiallergic, immunosuppressive effect. It is used, for example as emergency aid for the relief of severe allergic reactions, withdrawal from anaphylactic shock. In the instructions to the drug administration also stated that its use is indicated for the treatment of “severe infectious diseases (in combination with antibiotics)”.